Benzinga | May 14, 2021 08:17AM EDT

Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients

* Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML).

* Data come from two Phase 1 dose-escalation studies that are evaluating FT516 and FT538 as monotherapy.

* As of the data cutoff date of April 16, five of 12 patients had achieved an objective response with complete leukemic blast clearance in the bone marrow.

* Includes 3 complete remission with incomplete hematologic recovery (CRi), 1 morphologic leukemia-free state in FT516 (n=9) study and one CRi in FT538 (n=3) study.

* Of the four patients achieving a CRi, one patient successfully proceeded to allogeneic stem cell transplant, and the other three patients remained on-study and in remission without further therapeutic intervention, two of whom remained in remission having been on-study for more than six months.

* No dose-limiting toxicities, and no cases of any grade of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease, were observed.

* Price Action: FATE shares are up 1.45% at $72.55 in the premarket session on the last check Friday.